New Jersey Healthcare
Compliance Guide

New Jersey presents a dynamic, yet generally favorable, regulatory landscape for healthcare companies, including those leveraging telehealth. The state has actively embraced telehealth, particularly accelerated by the COVID-19 pandemic, codifying many emergency measures into permanent law. This has fostered an environment conducive to innovation, though strict adherence to professional practice standards and corporate compliance remains paramount. Key regulatory bodies include the New Jersey State Board of Medical Examiners, the New Jersey Board of Nursing, and the New Jersey Board of Pharmacy, all operating under the Division of Consumer Affairs within the Department of Law and Public Safety. These boards are rigorous in enforcing professional licensure, scope of practice, and prescribing rules. New Jersey maintains a nuanced stance on the Corporate Practice of Medicine (CPOM), which necessitates careful structuring for non-physician-owned entities. Recent legislative actions have focused on expanding access to care, refining telehealth regulations, and addressing public health concerns, such as opioid prescribing and mental health access. The state's commitment to patient protection and quality of care is evident in its detailed regulations, requiring healthcare businesses to adopt robust compliance programs. Companies expanding into New Jersey must navigate these regulations with precision, ensuring their operational models align with state-specific CPOM interpretations, telehealth modalities, and provider scope of practice limitations. The business climate is generally supportive of healthcare growth, but the regulatory framework demands a proactive and informed compliance strategy.

New Jersey enforces the Corporate Practice of Medicine (CPOM) doctrine, albeit with some statutory exceptions and a degree of judicial interpretation rather than a single, overarching statute explicitly prohibiting it. The legal basis for CPOM in New Jersey primarily stems from the Professional Service Corporation Act (N.J.S.A. 14A:17-1 et seq.) and various professional licensing statutes, which implicitly restrict the practice of medicine to licensed individuals or entities solely owned by licensed professionals. The core principle is that a lay corporation cannot employ physicians to practice medicine, nor can it control the professional judgment of licensed practitioners. This is designed to prevent commercial interests from interfering with patient care decisions. The Professional Service Corporation Act allows licensed professionals (e.g., physicians, dentists, chiropractors) to form professional corporations (PCs) or professional limited liability companies (PLLCs), which must be owned and controlled by licensed individuals of the same profession. This means a general business corporation cannot own a medical practice. Consequently, non-physicians generally cannot own a medical practice in New Jersey. However, there are exceptions and alternative structures. For instance, hospitals and certain non-profit entities are typically exempt from CPOM restrictions. For-profit entities, including telehealth companies, medspas, dental practices, and wellness clinics, must carefully structure their operations to avoid CPOM violations. This often involves a Management Services Organization (MSO) model, where a non-physician-owned MSO provides administrative, non-clinical services (e.g., billing, marketing, IT, real estate) to a physician-owned professional entity (PC or PLLC). The MSO cannot dictate clinical decisions, employ licensed professionals who provide patient care, or engage in fee-splitting that constitutes payment for referrals or professional services. The professional entity must retain full control over all clinical aspects, including hiring/firing of clinical staff, setting professional fees, and making treatment decisions. Dental practices operate under similar restrictions, requiring ownership by licensed dentists. Medspas and wellness clinics offering medical services (e.g., injectables, laser treatments, IV therapy) must ensure the medical component is owned and supervised by a licensed physician or other appropriately licensed professional, adhering to the same CPOM principles. Any arrangement where a lay entity exerts control over medical judgment or receives a percentage of professional fees without providing a commensurate, fair market value for non-clinical services risks violating CPOM and anti-kickback statutes. New Jersey's CPOM enforcement, while not as aggressive as some states, is real, and violations can lead to license revocation, civil penalties, and criminal charges.

New Jersey has a robust framework for telehealth, largely codified by P.L. 2017, c. 117 (N.J.S.A. 45:1-61 et seq.), which defines and regulates the practice of telemedicine and telehealth. This law explicitly permits the establishment of a valid provider-patient relationship via telehealth. The relationship can be established without a prior in-person visit, provided the practitioner satisfies the 'standards of care required for an in-person encounter.' This means the practitioner must conduct a thorough assessment, including obtaining a medical history and performing an appropriate examination, sufficient to diagnose and treat. Permitted modalities include real-time, interactive audio-visual communication (video conferencing), which is the preferred method for initial encounters and complex diagnoses. Audio-only telephone communication is generally permitted if it meets the standard of care and is appropriate for the service. Asynchronous 'store and forward' technology is also allowed, particularly for specialties like dermatology or radiology, where images or data are transmitted for review. However, a practitioner must use 'appropriate diagnostic and treatment protocols' and ensure the technology is secure and compliant with HIPAA. There are no specific telehealth registration requirements for practitioners beyond their standard professional licensure in New Jersey. However, out-of-state practitioners must be licensed in New Jersey to provide telehealth services to patients located in New Jersey, unless an interstate compact (e.g., IMLCC for physicians, Nurse Licensure Compact for nurses) applies and the practitioner holds a multistate license. Informed consent requirements are explicit. Before providing telehealth services, practitioners must obtain informed consent from the patient, documenting that the patient understands the nature of the services, potential risks, and benefits, and that they have the right to withdraw consent at any time. This consent must be documented in the patient's medical record. There are no geographic restrictions within New Jersey; practitioners licensed in the state can provide telehealth services to patients located anywhere in the state. However, practitioners must be mindful of the patient's physical location for prescribing controlled substances and for emergency protocols. The law emphasizes that telehealth services must meet the same standard of care as in-person services, and practitioners must maintain comprehensive medical records for all telehealth encounters.

New Jersey maintains stringent regulations for prescribing controlled substances via telehealth, largely aligning with federal DEA requirements while adding state-specific nuances. Generally, all schedules of controlled substances can be prescribed via telehealth if a valid practitioner-patient relationship has been established and the prescription is issued for a legitimate medical purpose in the usual course of professional practice. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. § 829(e)) generally requires an in-person medical evaluation prior to prescribing controlled substances via the internet. However, the COVID-19 public health emergency (PHE) waivers allowed for prescribing controlled substances via telehealth without a prior in-person exam. While the federal PHE ended, the DEA has extended certain flexibilities, and New Jersey's law (N.J.S.A. 45:1-61 et seq.) allows for establishing a patient relationship via telehealth, which implicitly permits prescribing if the standard of care is met. As of 2025-2026, the DEA is expected to finalize new rules regarding the Ryan Haight Act's applicability post-PHE, which may impact the ability to prescribe Schedule II-V controlled substances without an initial in-person visit for certain conditions. Practitioners must have a valid DEA registration and be licensed in New Jersey. PDMP checking (New Jersey Prescription Monitoring Program - NJPMP) is mandatory. Under N.J.S.A. 45:1-46, practitioners are required to review a patient's NJPMP history for the preceding year prior to prescribing any Schedule II, III, IV, or V controlled dangerous substance for a new course of treatment or if there has been a lapse in treatment for more than 30 days. This check must be documented in the patient's medical record. There are specific quantity and refill limitations for controlled substances, particularly opioids. For instance, N.J.S.A. 45:1-45.1 limits initial opioid prescriptions for acute pain to a five-day supply, with exceptions for chronic pain, cancer, or palliative care. Refills are generally restricted for Schedule II substances. Special rules for specific drug classes are critical. For GLP-1 agonists (e.g., for weight loss), while not controlled substances, prescribing must be medically appropriate, based on a comprehensive assessment, and adhere to FDA-approved indications or recognized off-label uses with proper informed consent. For testosterone (a Schedule III controlled substance), prescribing via telehealth requires careful adherence to the Ryan Haight Act's principles, ensuring medical necessity and appropriate monitoring. For stimulants (e.g., Adderall, Ritalin, Schedule II), the requirements are even stricter due to their high potential for abuse. Prescribing stimulants via telehealth, especially for initial diagnoses, demands a thorough evaluation, often requiring an in-person component or extensive documentation to justify the telehealth-only approach, especially if federal waivers expire. Practitioners must exercise extreme caution and ensure all prescribing aligns with the highest standards of care and federal/state regulations.

New Jersey has a progressive, though not fully autonomous, framework for advanced practice nurses (APNs) and physician assistants (PAs), while delegation for medical assistants is more restrictive. Advanced Practice Nurses (APNs) in New Jersey, including Nurse Practitioners (NPs), are granted significant, but not full, practice authority. Under N.J.S.A. 45:11-49 et seq., APNs can diagnose, treat, and prescribe medications, including controlled substances, within their scope of practice. However, they are required to practice in collaboration with a physician. While the term 'collaborative practice agreement' is often used, New Jersey's statute specifies a 'joint protocol' or 'attestation of collaboration' with a physician. This protocol outlines the APN's scope of practice, the physician's availability for consultation, and the referral process. It does not necessarily require direct physician supervision for every patient encounter but mandates a formal relationship ensuring physician oversight and consultation when needed. The APN is independently responsible for their actions within their scope. Physician Assistants (PAs) in New Jersey also operate under a collaborative agreement with a supervising physician, as outlined in N.J.S.A. 45:9-27.13 et seq. PAs can perform medical services that are delegated by their supervising physician and are within the PA's education, training, and experience. The supervising physician is responsible for the overall care of the patient and must be readily available for consultation. The scope of practice for PAs is defined by the supervising physician's practice and the PA's demonstrated competence. Direct supervision is not always required, but the physician must routinely review the PA's charts and be available for immediate consultation. For Medical Assistants (MAs), New Jersey's regulations are quite strict, particularly in settings like medspas. MAs are generally limited to administrative and basic clinical tasks that do not require independent medical judgment or licensure. They cannot diagnose, treat, prescribe, or perform invasive procedures. In a medspa setting, procedures like injectables (e.g., Botox, fillers), advanced laser treatments, or IV therapy must be performed by a licensed physician, APN, or PA, or delegated by a physician to another licensed professional (e.g., RN) within their scope of practice and under appropriate supervision. MAs cannot perform these procedures. Delegation rules for MAs are typically limited to tasks such as taking vital signs, preparing patients for exams, and assisting licensed practitioners. Any delegation must be within the MA's training and under direct supervision by a licensed professional. Unlicensed personnel performing tasks requiring medical licensure is a significant compliance risk in New Jersey.

Navigating New Jersey's Corporate Practice of Medicine (CPOM) doctrine necessitates careful business structuring, with the Professional Corporation (PC) / Management Services Organization (MSO) model being the most common compliant approach. Professional Corporations (PCs) or Professional Limited Liability Companies (PLLCs) are required for licensed professionals (e.g., physicians, dentists, chiropractors) to provide professional services. These entities must be owned by licensed individuals of the same profession (e.g., a medical PC must be owned by physicians). This structure ensures that clinical decision-making and patient care remain under the control of licensed professionals, thereby complying with CPOM. Management Services Organizations (MSOs), which are typically non-physician-owned, enter into a Management Services Agreement (MSA) with the professional entity. The MSO provides all the non-clinical, administrative, and business support services, such as billing, coding, marketing, IT, human resources for non-clinical staff, facilities management, and equipment leasing. The MSA must clearly delineate the services provided, and the compensation paid by the PC to the MSO must be at fair market value (FMV) for those services. This is crucial to avoid violations of anti-kickback statutes and prohibitions against illegal fee-splitting. Fee-splitting rules in New Jersey prohibit licensed professionals from sharing professional fees with unlicensed individuals or entities in exchange for referrals or for the provision of professional services. The MSO's compensation must be structured as a fixed fee, a cost-plus arrangement, or a percentage of collections that is demonstrably FMV for the services rendered and does not vary based on the volume or value of referrals. Percentage-based fees are scrutinized heavily and must be structured carefully to avoid being construed as illegal fee-splitting. Management Services Agreement (MSA) requirements are critical. The MSA must: 1. Clearly separate clinical and non-clinical responsibilities. 2. Grant the professional entity full control over all clinical decisions, hiring/firing of clinical staff, and setting professional fees. 3. Specify FMV compensation for the MSO's services. 4. Prohibit the MSO from interfering with the professional judgment of the licensed practitioners. 5. Include provisions for HIPAA compliance and data security. Structuring ownership for compliance involves ensuring the PC is 100% owned by licensed professionals, while the MSO can be owned by non-physicians or investors. This separation of ownership and control between clinical and administrative functions is the cornerstone of the compliant PC-MSO model. Companies must also consider forming a New Jersey professional entity (PC or PLLC) and registering their MSO as a foreign or domestic business entity in New Jersey. Careful legal review of all agreements (MSA, employment contracts, leases) is essential to ensure compliance with New Jersey's specific CPOM, anti-kickback, and fee-splitting regulations.

New Jersey's regulatory landscape continues to evolve, with several key developments and pending legislation impacting telehealth, CPOM, and prescribing practices. In 2024-2025, the state legislature has been active in refining healthcare access. One significant area of focus is mental health and substance use disorder treatment via telehealth. While specific bill numbers are subject to legislative session, there has been ongoing discussion and proposed legislation to ensure parity in reimbursement for telehealth mental health services and to expand access to medication-assisted treatment (MAT) through virtual platforms. Another area of legislative interest is the clarification of scope of practice for various allied health professionals, particularly in the context of delegation and supervision in evolving care models like medspas and wellness clinics. While no major overhauls to CPOM are anticipated, there are continuous efforts to ensure regulatory clarity for new business models. Regarding controlled substance prescribing, New Jersey is closely monitoring federal developments post-COVID-19 PHE, particularly the DEA's final rules on the Ryan Haight Act's 'in-person' requirement for initial prescriptions of controlled substances via telehealth. State regulations may be adjusted to align with or supplement these federal changes. There have been board actions by the New Jersey State Board of Medical Examiners and the Board of Nursing focusing on improper prescribing practices, particularly for opioids and stimulants, and on unlicensed individuals performing medical procedures in medspa settings. These enforcement actions underscore the boards' commitment to patient safety and adherence to scope of practice and CPOM. New Jersey is a member of the Nurse Licensure Compact (NLC), allowing nurses with multistate licenses to practice in NJ. The state is also a signatory to the Interstate Medical Licensure Compact (IMLC), facilitating an expedited pathway for physicians licensed in other compact states to obtain a New Jersey license. There are ongoing discussions about joining other compacts, such as the Psychology Interjurisdictional Compact (PSYPACT), to further expand telehealth access for mental health services. These compacts streamline licensure for out-of-state providers, which is a significant development for telehealth companies seeking to expand their practitioner base.

For healthcare companies entering or expanding in New Jersey, a meticulous, multi-faceted compliance strategy is essential. Here's actionable guidance: 1. CPOM Compliance First: Do not assume your existing structure is compliant. If you are a non-physician-owned entity providing or arranging medical services, immediately engage counsel to establish a compliant Professional Corporation (PC) / Management Services Organization (MSO) model. Ensure the PC is owned solely by New Jersey-licensed physicians and that the MSO's services and compensation are at fair market value and documented in a robust Management Services Agreement (MSA). 2. Licensure & Credentialing: All providers (physicians, NPs, PAs, etc.) must hold current, unrestricted New Jersey licenses. For telehealth, out-of-state providers must either obtain an NJ license or qualify under an interstate compact (e.g., IMLCC, NLC). Verify and document all provider credentials rigorously. 3. Telehealth Protocols: Develop and implement clear telehealth policies and procedures. This includes detailed informed consent processes, protocols for establishing a valid practitioner-patient relationship remotely, guidelines for appropriate technology (secure, HIPAA-compliant), and emergency protocols for patients experiencing adverse events during a telehealth encounter. 4. Prescribing Adherence: For controlled substances, ensure strict adherence to New Jersey's NJPMP requirements (mandatory checks and documentation). Implement policies for quantity limits, refill restrictions, and specific rules for high-risk medications (e.g., stimulants, opioids, GLP-1s). Train providers on the latest DEA guidance regarding telehealth prescribing post-PHE. 5. Scope of Practice Review: Clearly define and enforce the scope of practice for all clinical staff. For NPs and PAs, ensure valid, current collaborative agreements or joint protocols are in place. Be extremely cautious with delegation to unlicensed personnel, especially in medspa or wellness settings; typically, only licensed professionals can perform medical procedures. 6. Anti-Kickback & Fee-Splitting: Review all financial arrangements, including employment contracts, vendor agreements, and MSO fees, to ensure they comply with anti-kickback statutes and fee-splitting prohibitions. All compensation must be for legitimate services at fair market value, not for referrals. 7. Data Security & Privacy: Implement robust HIPAA-compliant security measures for all patient data, especially with telehealth modalities. Conduct regular risk assessments. 8. Timeline Expectations: Obtaining New Jersey medical licenses can take 3-6 months. Entity formation (PC, MSO) and contract drafting can take 1-3 months. Factor in these timelines for your launch strategy. Common Pitfalls to Avoid: Unlicensed individuals performing medical procedures, non-compliant MSO structures (e.g., MSO controlling clinical decisions), illegal fee-splitting, and inadequate documentation for telehealth encounters or controlled substance prescribing. Proactive legal counsel specializing in New Jersey healthcare law is indispensable.